Information for providers about therapeutic treatments for COVID-19

Nearly 40 percent of all Massachusetts residents may be eligible for therapeutics to treat early mild-to-moderate COVID-19. Note that treatment should begin as soon as possible after diagnosis of COVID.

Table of Contents


The U.S. Food and Drug Administration (FDA) has approved or issued emergency use authorizations (EUA) for several therapeutics for treatment of early mild-to-moderate COVID-19 in high-risk patients:

  • The preferred agent at this time is the oral antiviral nirmatrelvir boosted with ritonavir (PAXLOVID) begun within 5 days of symptom onset. 
    • Similar effectiveness can be achieved with the intravenous antiviral remdesivir (VEKLURY) which requires infusion on 3 consecutive days and must be started within 7 days of symptom onset.
  • If neither of these agents is available or appropriate, the monoclonal antibody bebtelovimab may be given as a single intravenous injection within 7 days of symptom onset.
  • Finally, if none of these therapeutics is available or appropriate, the oral medication molnupiravir may be given starting within 5 days of symptom onset.

Three previously authorized monoclonal antibodies are no longer authorized due to the presence of variants that reduce their effectiveness: Casirivimab/imdevimab (REGEN-COV)Bamlanivimab/etesevimab and Sotrovimab.

A preventive treatment called Evusheld is used before someone gets COVID-19 and is recommended for people with moderate to severe immunocompromise. Evusheld is not for the treatment of COVID-19 symptoms. It is not given to someone after they have been exposed to COVID-19. Learn more about Evusheld.

Use of monoclonal antibodies or antiviral medications is not a substitute for vaccination against COVID-19. Everyone is still encouraged to get vaccinated as soon as they can, whether it is a first, second or booster dose.



Anti-SARS-CoV2 monoclonal antibodies and oral antivirals are available through state-funded sites located across the Commonwealth.

Transportation to a treatment site should NOT be a barrier to care for patients diagnosed with COVID-19. Sites will work with your patient to arrange for transportation to and from the treatment site closest to their home.  There is no cost to the patient for this transportation.

Site Phone or email Fax Website
Athol* 508-635-0132 Gothams Referral Form
Everett 978-367-9946

COVID-19 Treatment Clinic (

Fairhaven/New Bedford 508-973-2659 508-973-2660 Southcoast Health
Holyoke* 508-948-3404 Gothams Referral Form
Hyannis 508-534-7103 508-568-1650 Cape Cod Health
Lowell* 508-974-3474 Gothams Referral Form
Pittsfield 855-262-5465   Berkshire Health Systems
Plymouth* 508-635-0126 Gothams Referral Form
Worcester 800-431-5151   UMass Memorial Health

*Download: Referral Form for monoclonal antibody and antiviral therapies at these Gothams managed sites.

  • Treatments are available widely via retail pharmacies across the Commonwealth.
  • COVID-19 treatments should be considered for all your patients and given to all patients appropriate for treatment. This group includes nearly 40 percent of all MA residents eligible due to heart, lung, liver, or kidney disease, diabetes, pregnancy, dementia, cancer, disability, substance use disorder, mental health disorder, age over 65, overweight/obesity and immunocompromised. View the full CDC list of medical conditions
  • Massachusetts has supply available to meet the needs of all residents who can benefit from these treatments.
  • Individuals may qualify for our in-home treatment program. Visit to learn more about eligibility.
  • Telehealth is available for individuals 18 or older living in Massachusetts who test  positive for COVID-19 and are experiencing symptoms. This telehealth service can determine if Paxlovid may be an option. If it is, pickup at a pharmacy or free overnight delivery is available. More at

Additionally, hospitals and other healthcare providers throughout Massachusetts serve as sites for distribution of COVID-19 therapeutics and will administer monoclonal antibodies and remdesivir and dispense oral antiviral therapy as supplies are available. The COVID-19 Therapeutics Locator can be used to locate sites offering monoclonal antibodies and antiviral therapies. For referrals to hospital sites, providers should use the contact number for the site listed on the site in locator map. Patients or their representative should follow the instructions provided by the healthcare provider as to how to receive the dispensed medication at the COVID-19 therapeutics site.

COVID-19 Therapeutic Locator

If you are having difficulty viewing the dashboard on a mobile or tablet device, you can link to the mobile view of the COVID-19 Therapeutic Locator or open an accessible view of the raw data.

COVID-19 Therapeutic Look Up Tool

If you are having difficulty viewing the table on a mobile or tablet device, you can link to the mobile view of the COVID-19 Therapeutic Lookup List or open an accessible view of the raw data.

Oral antiviral therapy will also be available through prescription requests and distributed through community health centers (CHC) in areas with a high burden of COVID-19. For patients who are cared for through the CHC, oral antivirals will be prescribed by CHC clinicians and filled through the CHC pharmacy. 

As oral antiviral therapies become more available, the number of sites dispensing the medication will increase.

Information for patients in multiple languages